Literature DB >> 23229021

Mesenchymal stem cells modified with miR-126 release angiogenic factors and activate Notch ligand Delta-like-4, enhancing ischemic angiogenesis and cell survival.

Feng Huang1, Xiao Zhu, Xin-Qun Hu, Zhen-Fei Fang, Liang Tang, Xiao-Ling Lu, Sheng-Hua Zhou.   

Abstract

The endothelial cell-specific microRNA (miRNA), miR-126, is considered a master regulator of physiological angiogenesis. Transplanted mesenchymal stem cells (MSCs) release soluble factors contributing to neoangiogenesis and cardiac repair. Therefore, we hypothesized that the over-expression of miR-126 may prolong MSC survival and enhance the cell secretome, thereby improving post-infarction angiogenesis and cardiac function. In this study, MSCs harvested from male C57BL/6 mouse bone marrow were infected in vitro with miR-126 (MSC(miR-126)) by using recombinant lentiviral vectors; the control cells were either non-transfected or transduced with mock vectors (MSC(null)). The results showed an increased secretion of angiogenic factors and a higher resistance against hypoxia in MSC(miR-126) compared with the control cells. The expression of the Notch ligand Delta-like (Dll)-4 in the MSC(miR-126) group was also increased. For in vivo experiments, MSC(miR-126) cultures were intramyocardially injected into the infarct region of the hearts of female C57BL/6 mice (an acute myocardial infarction model) who had undergone ligation of the left anterior descending coronary artery. The survival of MSC(miR-126) cultures, determined by Sry expression, was increased at 7 days after transplantation. MSC(miR-126)-treated animals showed significantly improved cardiac function as assessed by echocardiography 2 weeks later. The expression levels of angiogenic factors and Dll-4 in the infarcted myocardium were further increased by MSC(miR-126) compared with MSCs or MSC(null) cultures. Furthermore, fluorescent microsphere and histological studies revealed that myocardial blood flow and microvessel density were significantly increased in the MSC(miR-126)-transplanted animals. In addition, we found increased immature vessel proliferation following the transplantation of MSC(miR-126) cultures in which the expression of Dll-4 had been knocked down. However, blood vessels with lumen were barely detected, which indicated that Dll-4 plays a key role in tubulogenesis. We conclude that the transplantation of MSCs overexpressing miR-126 can further enhance functional angiogenesis in the ischemic myocardium possibly by the secretion of angiogenic factors and the activation of Dll-4, thus increasing MSC survival. Therefore, MSCs modified with miR-126 may represent a novel and efficient therapeutic approach for ischemic angiogenesis and the improvement of cardiac function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23229021     DOI: 10.3892/ijmm.2012.1200

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  51 in total

Review 1.  Developing miRNA therapeutics for cardiac repair in ischemic heart disease.

Authors:  Kai Zhu; Dingqian Liu; Hao Lai; Jun Li; Chunsheng Wang
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

2.  CLDN-1 promoted the epithelial to migration and mesenchymal transition (EMT) in human bronchial epithelial cells via Notch pathway.

Authors:  Jing Lv; Baohua Sun; Zhitao Mai; Mingming Jiang; Junfeng Du
Journal:  Mol Cell Biochem       Date:  2017-03-18       Impact factor: 3.396

3.  MiR-126 Contributes to Human Umbilical Cord Blood Cell-Induced Neurorestorative Effects After Stroke in Type-2 Diabetic Mice.

Authors:  Jieli Chen; Ruizhuo Ning; Alex Zacharek; Chengcheng Cui; Xu Cui; Tao Yan; Poornima Venkat; Yi Zhang; Michael Chopp
Journal:  Stem Cells       Date:  2016-01       Impact factor: 6.277

4.  The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.

Authors:  Salem Y Mohamed; Randa Mohamed Kaf; Mona Mostafa Ahmed; Amira Elwan; Hassan R Ashour; Amr Ibrahim
Journal:  J Gastrointest Cancer       Date:  2019-12

Review 5.  New strategies for improving stem cell therapy in ischemic heart disease.

Authors:  Peisen Huang; Xiaqiu Tian; Qing Li; Yuejin Yang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 6.  Regulatory non-coding RNAs in acute myocardial infarction.

Authors:  Yuan Guo; Fei Luo; Qiong Liu; Danyan Xu
Journal:  J Cell Mol Med       Date:  2016-11-23       Impact factor: 5.310

7.  The miR-590-3p/VEGFA axis modulates secretion of VEGFA from adipose-derived stem cells, which acts as a paracrine regulator of human dermal microvascular endothelial cell angiogenesis.

Authors:  Yang Sun; Xiang Xiong; Xiancheng Wang
Journal:  Hum Cell       Date:  2020-04-10       Impact factor: 4.174

Review 8.  Noncoding RNA as regulators of cardiac fibrosis: current insight and the road ahead.

Authors:  Hui Tao; Jing-Jing Yang; Wei Hu; Kai-Hu Shi; Zi-Yu Deng; Jun Li
Journal:  Pflugers Arch       Date:  2016-01-20       Impact factor: 3.657

Review 9.  MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine.

Authors:  V Sala; S Bergerone; S Gatti; S Gallo; A Ponzetto; C Ponzetto; T Crepaldi
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

10.  Biomaterials functionalized with MSC secreted extracellular vesicles and soluble factors for tissue regeneration.

Authors:  Meadhbh Á Brennan; Pierre Layrolle; David J Mooney
Journal:  Adv Funct Mater       Date:  2020-03-11       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.